首页> 外文期刊>Archives of medical research >Receptor for Advanced Glycation End Products: A New Theraputic Target for Chronic Obstructive Pulmonary Disease?
【24h】

Receptor for Advanced Glycation End Products: A New Theraputic Target for Chronic Obstructive Pulmonary Disease?

机译:糖基化终末产物受体:慢性阻塞性肺疾病的新治疗靶点?

获取原文
获取原文并翻译 | 示例
           

摘要

Receptor for advanced glycation end products (RAGE), a multiligand receptor, has been suggested to be implicated in inflammatory response. However, its role in chronic obstructive pulmonary disease (COPD) has not been well elucidated. Recently, several studies reported RAGE and its common ligands were upregulated in airways and lung tissues from COPD smokers. Moreover, inhibition of RAGE activation significantly attenuated cigarette smoke extract or bacteria-induced pulmonary inflammation. Based on these findings, a conclusion could be made that ligand-activated RAGE may play a key role in COPD and thus RAGE could be a new therapeutic target for COPD. ? 2013 IMSS.
机译:晚期糖基化终产物(RAGE)的受体,一种多配体受体,被认为与炎症反应有关。但是,其在慢性阻塞性肺疾病(COPD)中的作用尚未得到很好的阐明。最近,一些研究报告说,COPD吸烟者的气道和肺组织中的RAGE及其常见配体被上调。此外,抑制RAGE活化可显着减弱香烟烟雾提取物或细菌引起的肺部炎症。基于这些发现,可以得出结论,配体激活的RAGE可能在COPD中起关键作用,因此RAGE可能成为COPD的新治疗靶标。 ? 2013年IMSS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号